Key Details
Price
$91.32Last Dividend
$0.77Annual Revenue
$27.12 BAnnual EPS
$4.50Annual ROE
25.77%Beta
0.16Events Calendar
Next earnings date:
Feb 06, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 06, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 13, 2024Next split:
N/ARecent split:
Jan 28, 2013Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
At the end of the last trading day, Gilead Sciences (GILD) was priced at $91.41, which represents a decrease of 0.51% compared to the day before.
Lately, users of Zacks.com have been focusing on Gilead (GILD). Therefore, it's important to take a look at what the stock might offer.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) has announced that its leaders will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2025, starting at 11:15 a.m. Pacific Time. You can watch the live webcast at investors.gilead.com, and a replay will be available for at least 30 days after the event. Gilead Sciences, Inc. is a biopharmaceutical company focused on research and development.
GILD has shown consistent performance in 2024, thanks to a new drug approval, encouraging data results, and solid quarterly earnings. We think there is still potential for further growth, considering GILD's strong fundamentals.
Gilead has announced that the FDA has given Trodelvy a second Breakthrough Therapy designation for treating extensive-stage small cell lung cancer.
Discover the potential of your investment portfolio by exploring these high-yield value stocks: PBI, GPOR, KINS, NATL, and GILD.
Gilead's shares have risen sharply thanks to the successful introduction of Livdelzi for PBC and encouraging progress with lenacapavir for HIV prevention. The approval of Livdelzi and its strong market potential, along with Gilead's strong HIV product lineup, set the company up for considerable revenue growth. Even with competition and some debt, Gilead remains financially healthy, boasting strong cash flow and manageable debt levels.
The CHMP suggests that Gilead's seladelpar, when used with ursodeoxycholic acid, should be approved for treating primary biliary cholangitis in adults.
Gilead (GILD) has received an upgrade to a Zacks Rank #2 (Buy), indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive recommendation for seladelpar. This treatment is for adults with primary biliary cholangitis (PBC) who do not respond well to ursodeoxycholic acid (UDCA) alone, or for those who cannot tolerate UDCA. The final decision from the European Commission is still pending.
FAQ
- What is the primary business of Gilead Sciences?
- What is the ticker symbol for Gilead Sciences?
- Does Gilead Sciences pay dividends?
- What sector is Gilead Sciences in?
- What industry is Gilead Sciences in?
- What country is Gilead Sciences based in?
- When did Gilead Sciences go public?
- Is Gilead Sciences in the S&P 500?
- Is Gilead Sciences in the NASDAQ 100?
- Is Gilead Sciences in the Dow Jones?
- When was Gilead Sciences's last earnings report?
- When does Gilead Sciences report earnings?
- Should I buy Gilead Sciences stock now?